Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 23 May 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Imatinib mesylate brings promise as a treatment for advanced gastrointestinal stromal tumors

A recent trial of a selective tyrosine kinase inhibitor offers hope for the development of drugs to treat gastrointestinal stromal tumors, reports the latest issue of The New England Journal of Medicine.

News image

fiogf49gjkf04

The constitutive activation of the KIT receptor tyrosine kinase is known to be a key step in the pathogenesis of gastrointestinal stromal tumors.

Inhibitors of this kinase are therefore highly attractive to scientists attempting to develop new therapies for the treatment of such tumors.

One such inhibitor, imatinib mesylate, a selective tyrosine kinase inhibitor, has previously been shown in preclinical models and preliminary clinical studies to have activity against such tumors.

Now scientists have conducted an open-label, randomized trial to evaluate this activity in patients with advanced gastrointestinal-stromal tumor.

The multi-center trial was carried out to assess the anti-tumor response and the safety and tolerability of the drug, with additional pharmacokinetic studies being carried out in a subgroup of the patients recruited to the trial.

A total of 147 patients were randomly assigned to receive either 400 mg or 600 mg of imatinib daily.

Overall, 79 patients (almost 54%) had a partial response, 41 patients (just under 28%) had stable disease, and for technical reasons, response could not be evaluated in 7 patients (4.8%).

However, no patient had a complete response to the treatment.

The median duration of response had not been reached after a median follow-up of 24 weeks after the onset of response.

Although early resistance to imatinib was noted in 20 patients (13.6%), therapy was well tolerated, despite mild-to-moderate edema, diarrhea, and fatigue being common side effects.

Partial response to treatment was seen in over half of all patients
New England Journal of Medicine

Gastrointestinal or intra-abdominal hemorrhage also occurred in approximately 5% of patients.

There were no significant differences in toxic effects or response between the two doses, and imatinib was well absorbed, with pharmacokinetics similar to those reported in patients with chronic myeloid leukemia.

Commenting on the findings of the trial, Dr George D. Demetri said, "Imatinib induced a sustained objective response in more than half of patients with an advanced unresectable or metastatic gastrointestinal stromal tumor."

He added that inhibition of the KIT signal-transduction pathway is a promising treatment for advanced gastrointestinal stromal tumors, which resist conventional chemotherapy.

N Engl J Med 2002; 347(7): 472-480
16 August 2002

Go to top of page Email this page Email this page to a colleague

 23 May 2018 
Management of perianal fistulas in Crohn’s disease
 23 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 23 May 2018 
High body mass index is and ulcerative colitis
 22 May 2018 
Worldwide H.pylori prevalence
 22 May 2018 
PPI and risk of stroke
 22 May 2018 
Online tool predicts bowel dysfunction severity prior to anterior resection
 21 May 2018 
PPI use and cognitive decline
 21 May 2018 
Depressive symptoms in IBD youth
 21 May 2018 
Fecal incontinence and quality of life in IBD
 18 May 2018 
Esophageal dilatation in clinical practice 
 17 May 2018 
IBD and later extraintestinal manifestations
 17 May 2018 
Repeat stool DNA testing
 17 May 2018 
IBS and chronic fatigue following GI infection
 16 May 2018 
Factors associated with fecal incontinence
 16 May 2018 
Diagnostic delay in Crohn's disease
 16 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 15 May 2018 
Guidelines for management of Crohn's
 15 May 2018 
New therapies for CDI
 15 May 2018 
Hep B in the Grey Zone
 14 May 2018 
Blood test for the diagnosis of fibrotic NASH
 14 May 2018 
Outcomes at bariatric centers of excellence
 14 May 2018 
Management of perianal fistulas in Crohn’s
 11 May 2018 
Detection of undiagnosed celiac disease
 11 May 2018 
Alcohol consumption and drug-induced liver injury
 10 May 2018 
Colorectal cancer screening
 10 May 2018 
Post‐operative complications in elderly IBD
 10 May 2018 
Fibrosis in patients with chronic hepatitis B
 09 May 2018 
Esophageal dilatation in clinical practice 
 09 May 2018 
Fecal incontinence
 09 May 2018 
Health problems and IBS
 07 May 2018 
Health problems and IBS
 07 May 2018 
Assessment of diminutive colorectal polyps
 07 May 2018 
Omitting antibiotics in uncomplicated acute diverticulitis
 04 May 2018 
National Institutes of Health workshop and obesity
 04 May 2018 
Factors associated with fecal incontinence
 04 May 2018 
Colorectal cancer screening and ethnic inequities
 03 May 2018 
Gastrointestinal ultrasound in IBD
 03 May 2018 
Ultransonography in postsurgical recurrence in Crohn's
 02 May 2018 
Symptom assessment in cirrhotic ascites
 02 May 2018 
Hep C antiviral treatment and liver cancer risk
 02 May 2018 
Chronic Hep B
 01 May 2018 
European guidelines on pancreatic cystic neoplasms
 01 May 2018 
Interferon‐free regimens in Hep C
 01 May 2018 
Age at IBD onset and extraintestinal complications
 30 April 2018 
Formula for preterm infants
 30 April 2018 
Primary antibiotic resistance and sequential therapy for H. pylori
 30 April 2018 
Patient-reported outcome measures in IBD trials
 27 April 2018 
Anxiety scale for chronic esophageal disease
 27 April 2018 
Disease activity in eosinophilic esophagitis
 27 April 2018 
Eastern and western practices for endoscopic resection of colorectal lesions
 26 April 2018 
Obesity and physical activity in diverticulosis
 26 April 2018 
Primary sclerosing cholangitis in the USA
 25 April 2018 
Central mediators of irinotecan-induced steatohepatitis
 25 April 2018 
Aspirin and pancreatic cancer
 25 April 2018 
Neuroimaging in Hep C
 24 April 2018 
Scoring system identifies cancer risk in Barrett's
 24 April 2018 
Microbiome in athletes vs sedentary subjects
 23 April 2018 
Genome-wide study on HBV-related acute-on-chronic liver failure
 23 April 2018 
Antibody suitable for further clinical development to complement existing therapeutic strategies for HCV
 23 April 2018 
Sleep deprivation and NAFLD in the USA

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us